Hostname: page-component-848d4c4894-2xdlg Total loading time: 0 Render date: 2024-06-22T13:33:35.639Z Has data issue: false hasContentIssue false
  • English
  • Français

MicroRNA-17 Control Osteoclasts Through RANKL Targeting in cholesteatoma

Presenting Author: Chen Xiaohua

Published online by Cambridge University Press:  03 June 2016

Chen Xiaohua  and
Qin Zhaobing
Chen Xiaohua
Affiliation:
The First Affiliated Hospital of Zhengzhou University
Qin Zhaobing
Affiliation:
The First Affiliated Hospital of Zhengzhou University
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.
Type
Abstracts
Information
The Journal of Laryngology & Otology , Volume 130 , Supplement S3: Abstracts for the 10th International Conference on Cholesteatoma , May 2016 , pp. S246
Copyright
Copyright © JLO (1984) Limited 2016 

Learning Objectives:

Objective: Cholesteatoma is characterized by a extraordinary extensive bone destruction in the middle ear and mastoid cavities. MicroRNAs (miRNAs) are posttranscriptional regulators of gene expression. The goal of this study was to investigate the posttranscriptional regulatory effects controlling bone destruction in cholesteatoma. Specifically, the potential role of microRNA-17 is to control osteoclasts through RANKL targeting in cholesteatoma.

Methods: Cholesteatoma, taking from patients at the time of surgery, were processed for RNA and protein extraction. Specimens of cholesteatoma and normal post-auricular auditory skin served as the control. Real-time reverse-transcription polymerase chain reaction was used to assess the expression levels of microRNA-17. Also, western blot analyses were used to assess microRNA-17's downstream target protein.

Results: MicroRNA-17 showed an down-regulation in cholesteatomas compared to normal skin. MicroRNA-17 showed 2.75 fold higher in expression in skins as compared to cholesteatomas (P = 0.019). The downstream target of miRNA-17, RANKL protein, was found to greatly increase in cholesteatomas.

Conclusions: This study specifically identified the down-regulation of miRNA-17 concurrent with the up-regulation of the receptor activator of NF-[Kappa]B ligand (RANKL), which activates osteoclasts and plays a significant role in the mechanism of bone destruction in cholesteatoma.

The results give a partial explanation for the more extensive bone destruction in the middle ear and mastoid cavities which has been observed in cholestatoma.